A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination with Pembrolizumab to Assess Safety and Immune Activation in Patients with Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer
A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination with Pembrolizumab to Assess Safety and Immune Activation in Patients with Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.